Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-20 of 20
Keywords: Galantamine
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Yvonne Freund-Levi, Victor Bloniecki, Bjørn Auestad, Ann Christine Tysen Bäckström, Marie Lärksäter, Dag Aarsland
Dement Geriatr Cogn Disord (2014) 38 (3-4): 234–244.
Published Online: 25 June 2014
...Yvonne Freund-Levi; Victor Bloniecki; Bjørn Auestad; Ann Christine Tysen Bäckström; Marie Lärksäter; Dag Aarsland Aims: To examine the effects of galantamine and risperidone on agitation in patients with dementia. Methods: A total of 100 patients with dementia and neuropsychiatric symptoms (mean...
Journal Articles
Johannes Kornhuber, Klaus Schmidtke, Lutz Frölich, Robert Perneczky, Stefanie Wolf, Harald Hampel, Frank Jessen, Isabella Heuser, Oliver Peters, Markus Weih, Holger Jahn, Christian Luckhaus, Michael Hüll, Hermann-Josef Gertz, Johannes Schröder, Johannes Pantel, Otto Rienhoff, Susanne A. Seuchter, Eckart Rüther, Fritz Henn, Wolfgang Maier, Jens Wiltfang
Dement Geriatr Cogn Disord (2009) 27 (5): 404–417.
Published Online: 01 April 2009
..., 2 clinical trials were conducted with patients suffering from MCI and mild to moderate Alzheimer’s Disease (AD). These trials aimed at evaluating the efficacy and safety of the combination of galantamine and memantine versus galantamine alone. Results: Here, we report on the scope and projects...
Journal Articles
Dement Geriatr Cogn Disord (2008) 25 (2): 178–185.
Published Online: 14 January 2008
...A. Kertesz; D. Morlog; M. Light; M. Blair; W. Davidson; S. Jesso; R. Brashear Background/Aims: The treatment of frontotemporal dementia (FTD) has been mainly symptomatic. Small randomized or open-label case control studies of neurotransmitters have been inconclusive. We tried galantamine in the 2...
Journal Articles
Keith Edwards, Donald Royall, Linda Hershey, David Lichter, Ann Hake, Martin Farlow, Florence Pasquier, Stewart Johnson
Dement Geriatr Cogn Disord (2007) 23 (6): 401–405.
Published Online: 03 April 2007
... by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric...
Journal Articles
Dement Geriatr Cogn Disord (2006) 21 (2): 120–129.
Published Online: 20 January 2006
... Alzheimer’s disease Acetylcholine Circadian rhythm Sleep disorders Cholinesterase inhibitors Galantamine Donepezil Rivastigmine Slow-wave sleep Original Research Article Dement Geriatr Cogn Disord 2006;21:120 129 DOI: 10.1159/000090630 Accepted: July 18, 2005 Published online: January 2, 2006...
Journal Articles
Guk-Hee Suh, Hee Yeon Jung, Chang Uk Lee, Byoung Hoon Oh, Sang-Kyu Lee, NamJin Lee, JaeHyun Kim, Baik Seok Kee, Daekwan Ko, Young-Hoon Kim, Young-Su Ju, InJa Hong, Sungku Choi
Dement Geriatr Cogn Disord (2005) 21 (1): 33–39.
Published Online: 15 December 2005
... of galantamine treatment. Methods: A total of 202 patients with mild to moderate Alzheimer’s disease participated in a 16-week, prospective, multi-center, randomized, double-blind galantamine trial in a Korean population. Patients were assessed at baseline and after 4, 8 and 16 weeks of randomized treatment...
Journal Articles
Henry Brodaty, Jody Corey-Bloom, Felix C.V. Potocnik, Luc Truyen, Michael Gold, Chandrasekhar Rao V. Damaraju
Dement Geriatr Cogn Disord (2005) 20 (2-3): 120–132.
Published Online: 19 August 2005
...Henry Brodaty; Jody Corey-Bloom; Felix C.V. Potocnik; Luc Truyen; Michael Gold; Chandrasekhar Rao V. Damaraju The primary objective of this study was to evaluate the efficacy and tolerability of a flexible dosing regimen (16 or 24 mg/day) of galantamine prolonged-release capsule (PRC) compared...
Journal Articles
S. López-Pousa, A. Turon-Estrada, J. Garre-Olmo, I. Pericot-Nierga, M. Lozano-Gallego, M. Vilalta-Franch, M. Hernández-Ferràndiz, V. Morante-Muñoz, A. Isern-Vila, E. Gelada-Batlle, J. Majó-Llopart
Dement Geriatr Cogn Disord (2005) 19 (4): 189–195.
Published Online: 16 March 2005
... patients, 40 initiated treatment with donepezil, 32 with galantamine, 30 with rivastigmine and 45 were part of a historical sample of the memory clinic patients between 1991 and 1996 that had not been treated with AChEIs. The average age was 73.7 years (SD = 6.9; range = 52–86), 67.3% were women, 78.2...
Journal Articles
Dement Geriatr Cogn Disord (2004) 18 (2): 217–226.
Published Online: 13 August 2004
...A. Kurz; B. van Baelen Data were derived from the Cochrane Collaboration meta-analyses of the efficacies of ginkgo, donepezil, rivastigmine and galantamine on changes in cognitive function in patients with dementia and, where necessary, were transformed to standardized mean differences...
Journal Articles
Keith R. Edwards, Linda Hershey, Laura Wray, Edward M. Bednarczyk, David Lichter, Martin Farlow, Stewart Johnson
Dement Geriatr Cogn Disord (2003) 17 (Suppl. 1): 40–48.
Published Online: 19 December 2003
.... A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12...
Journal Articles
Dement Geriatr Cogn Disord (2003) 17 (Suppl. 1): 32–39.
Published Online: 19 December 2003
... the treatment of DLB with acetylcholinesterase inhibitors. Encouraging results have been obtained from studies of DLB patients treated with rivastigmine, donepezil, and galantamine, but large-scale, controlled trials are needed to confirm the efficacy and safety of acetylcholinesterase inhibitors in patients...
Journal Articles
Dement Geriatr Cogn Disord (2003) 17 (1-2): 29–34.
Published Online: 11 December 2003
...Roger Bullock; Timo Erkinjuntti; Sean Lilienfeld; G GAL-INT-6 Study Group We evaluated the long-term cognitive effects and safety of galantamine 24 mg/day in patients with Alzheimer’s disease plus cerebrovascular disease (AD + CVD or mixed dementia). Subgroup analysis was performed of patients...
Journal Articles
Dement Geriatr Cogn Disord (2003) 15 (2): 79–87.
Published Online: 20 January 2003
...Rafael Blesa; Michael Davidson; Alexander Kurz; William Reichman; Bart van Baelen; Susanne Schwalen Galantamine (Reminyl ® ), a novel agent with a dual mode of action, modulates nicotinic acetylcholine receptors and inhibits acetylcholinesterase. Galantamine has consistently demonstrated a broad...
Journal Articles
Dement Geriatr Cogn Disord (2002) 15 (1): 26–33.
Published Online: 05 December 2002
..., and a 7-point clinical global impression of change scale that summarizes patients’ changes during treatment. We analyzed the narrative content of clinicians’ notes from a randomized, controlled trial of galantamine, an anti-Alzheimer’s disease drug, and identified varying degrees of improvement...
Journal Articles
Dement Geriatr Cogn Disord (2002) 14 (2): 84–89.
Published Online: 22 July 2002
...J. Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Angelika Mehnert Background: The economic impact of dementia on the Dutch health and social services is substantial. Objective: To predict the long-term economic impact of galantamine, a cholinesterase inhibitor, in the treatment of Dutch...
Journal Articles
Dement Geriatr Cogn Disord (2001) 12 (2): 69–77.
Published Online: 09 February 2001
... duration, designed to evaluate efficacy of treatment with galantamine or sabeluzole. In addition to patient demographics and baseline scores for Mini Mental State Examination, scores on the Disability Assessment for Dementia (DAD) and the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 11–18.
Published Online: 14 September 2000
... therapeutic benefit in AD. One of the most potent of these allosteric modulators is galantamine. As well as modulating nAChR, galantamine inhib- its AChE. The extent to which the clinical benefits of galantamine are attributable specifically to its nicotinic effects is uncertain and requires further...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 19–27.
Published Online: 14 September 2000
...Sean Lilienfeld; Wim Parys Galantamine, a novel treatment for Alzheimer’s disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase. In the Phase III clinical trial programme...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 3–10.
Published Online: 14 September 2000
... of Geriatric Medicine, Huddinge University Hospital, bStockholm Gerontology Research Center, cHM Queen Sophia s College of Nursing, Stockholm, Sweden Key Words Alzheimer s disease W Dementia W Galantamine W Outcome measures W Activities of daily living W Caregiver burden W Behavioural disturbances W...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 28–34.
Published Online: 14 September 2000
... and the impact of the disease on the caregiver. Therefore, increasing attention is being paid to clinically meaningful outcome measures, such as the Disability Assessment for Dementia (DAD) scale, the Neuropsychiatric Inventory (NPI), caregiver time and the Pittsburgh Sleep Quality Index (PSQI). Galantamine...